CSTL250117C30000
- 0.01
- 0.000.00%
Castle Biosciences Newsroom
Leerink Partners Maintains Castle Biosciences(CSTL.US) With Buy Rating, Announces Target Price $50
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $44
Canaccord Genuity Keeps Their Buy Rating on Castle Biosciences (CSTL)
Castle Biosciences Price Target Maintained With a $41.00/Share by Stephens & Co.
Castle Biosciences Analyst Ratings
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Analysts' Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
Canaccord Genuity Sticks to Its Buy Rating for Castle Biosciences (CSTL)
Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Castle Biosciences Analyst Ratings
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44
Strong Growth Prospects and Financial Health Support Buy Rating for Castle Biosciences
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $45